Bengt Å Johansson takes role as acting CEO of Dilafor. Anders Åsell is elected board member of Dilafor.
STOCKHOLM, October 25, 2010. Dilafor CEO Anders Åsell has decided to leave the company to assume the role as General Manager for Grifols in the Nordic countries. Bengt Å Johansson, chairman of Dilafor, takes on the role as acting CEO of Dilafor during the search for a replacement. Anders Åsell has been elected as new Dilafor board member.
”Under Anders management, Dilafor has successfully concluded a clinical Phase II study for the treatment of dystocia/protracted labor, and a clinical Phase I study for the treatment of severe malaria where the planning for Phase II trials is ongoing. Now we will search for Anders replacement, and for this process as for the continued development of Dilafor we are happy to have him still serving the company as board member”, says Bengt Å Johansson, chairman of the board.
For further information, please contact:
Bengt Å Johansson, Chairman of the Board, Dilafor AB
Tel: +46-706-80 47 62, e-mail: email@example.com
Dilafor AB is a Swedish R&D company focused on developing pharmaceutical products with low anticoagulant activity from heparin. The company has a balanced product portfolio with two projects in clinical development phase, tafoxiparin for the prevention and treatment of dystocia/protracted labor and sevuparin for the treatment of severe malaria. Dilafor is part of Karolinska Development.